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Recombinant proteins 
from Gallibacterium anatis induces partial 
protection against heterologous challenge 
in egg-laying hens
Susanne Elisabeth Pors1, Ragnhild Bager Skjerning1, Esben M. Flachs2 and Anders Miki Bojesen1*
Abstract 
Gallibacterium anatis is a Gram-negative bacterium and major cause of salpingitis and peritonitis in egg-laying hens, 
thereby contributing to decreased egg production and increased mortality among the hens. Due to widespread drug 
resistance and antigenic diversity, novel prophylactic measures are urgently required. The aim of the present study 
was to evaluate the cross-protective capacity of three recombinant proteins recently identified as potential vaccine 
candidates; GtxA-N, GtxA-C, and FlfA, in an in vivo challenge model. Nine groups of birds were immunized twice with 
each protein, respectively, with 14 days separation. Additionally, three groups served as non-immunized controls. 
After 3 weeks, the birds were challenged with either of three G. anatis strains: 12656-12, 7990 or IPDH 697-78, respec-
tively. Blood samples were taken at three different time points prior to challenge, as well as 48 h after challenge. All 
birds were euthanized and subjected to a post mortem procedure including scoring of lesions and sampling for bac-
terial growth. Moreover, ELISA assays were used to quantify antigen-specific IgG titers in serum. The results showed 
that all three proteins induced protection against the homologous strain 12656-12. No protein induced complete 
protection against strain 7990, although FlfA reduced the bacterial re-isolation rate. Moreover, immunization with 
GtxA-N and FlfA induced protection, while GtxA-C reduced the bacterial re-isolation, against strain IPDH 697-78. Thus 
although complete cross-protection against all three strains was not achieved, the results hold great promise for a 
new generation of immunogens in the search for novel prophylactic measures against G. anatis.
© 2016 Pors et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Current strategies to prevent and treat bacterial salpingi-
tis and peritonitis among egg-laying hens have not been 
able of effectively diminish the occurrence of the disease, 
which remains to be a common problem in modern poul-
try production. Salpingitis and peritonitis has a profound 
negative impact on egg production and increases the 
mortality among commercial layers [1–3]. Among the 
bacterial agents associated with salpingitis and peritoni-
tis is the Gram-negative bacterium Gallibacterium ana-
tis [4]. Even though the pathogenesis of salpingitis and 
peritonitis caused by G. anatis has not been completely 
elucidated [5], a number virulence factors have been 
reported [6]. Gallibacterium anatis can also be found 
as part of the normal microbiota of the chicken upper 
respiratory tract and lower genital tract [7, 8]. Unfortu-
nately, G. anatis field strains are characterized by a high 
antigenic diversity [9, 10], and widespread antibiotic 
resistance has been reported [11], making current treat-
ments inefficient on a broad scale. Consequently, there is 
a high demand for new innovative prevention strategies, 
such as a broadly-protective vaccine, to efficiently pre-
vent infections caused by G. anatis.
In general, development of a successful vaccine induc-
ing broad heterologous protection against bacteria with 
high antigenic diversity is particularly challenging [12]. 
The antigenic diversity demands the use of common 
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antigens providing a broadly-based immunity, which can 
be challenging to identify. For other poultry-associated 
pathogens showing similar high antigen variability, e.g., 
Pasteurella multocida and Escherichia coli, some suc-
cessful attempts have been made to identify vaccine can-
didates with a broad protection [13–15]. In the recent 
years, a pan-genomic reverse vaccinology approach has 
been developed to identify highly conserved antigens 
[16, 17] by which, Bager et al. identified a number of con-
served and potential immunogens of G. anatis [18]. Some 
of these have proven to have an immunogenic potential 
against homologous challenge, including the recombi-
nant forms of the N-terminal of GtxA, a large cytolytic 
RTX toxin with both the haemolytic and leukotoxic activ-
ity [19, 20], as well as the F17-like fimbrial protein FlfA 
subunit of the F17-like fimbriae [21]. These proteins are 
widespread among the Gallibacterium strains of different 
origin [19, 22], and therefore represent promising candi-
dates for induction of protective immunity in a serotype-
independent manner.
In the present study, we investigated the cross-protec-
tive potential of the three potential vaccine candidates; 
GtxA-N (N-terminal of GtxA), GtxA-C (C-terminal of 
GtxA) and FlfA, against three different serotypes of G. 
anatis using an in vivo challenge model.
Materials and methods
Strains of Gallibacterium anatis used for heterologous 
challenge
Three different strains of G. anatis biovar heamolytica 
were used to study the cross-protective potential; the 
homologous strain 12656-12 (biovar 4) isolated from liver 
lesions in a Danish chicken [1], as well as strain IPDH 
697-78 (biovar 15), isolated from a diseased chicken in 
Germany [7], and strain 7990 (biovar 3), isolated from a 
Mexican chicken with lesions [19].
Birds and housing
Two experiments were used in the present study: (1) Ini-
tial validation of the immunogenic potential of all three 
proteins with homologous challenge (strain 12656-12), 
using 80 Isa Brown layers, 19 weeks of age, and (2) Eval-
uation of protection against homologous (strain 12656-
12) and heterologous challenge (strain IPDH 697-78 and 
7990), using a total of 240 Isa Brown layers, 18  weeks 
of age. All birds were purchased from a commercial 
breeder, housed on the floor in groups of 20 birds with 
access to ad  libitum feed, water and nesting material. 
At arrival, the birds were allowed one week of accli-
matization before initiation of the experiments. Prior 
to immunization, all birds were swabbed in the cloaca. 
The swabs were cultivated on brain heart infusion (BHI) 
agar (Oxoid) with 5% citrated bovine blood in sealed 
plastic bags at 37  °C overnight to test for the presence 
of G. anatis. A total of 25 birds showed feather pecking 
behavior and were removed from the study between day 
14 and day 35, in order to prevent development canni-
balism among the birds. All experiments were approved 
by the Danish Animal Inspectorate (license number 
2012-15-2934-00339).
Immunization of laying hens
A total of 80 birds were immunized with either one of 
the following recombinant proteins; GtxA-N, GtxA-C or 
FlfA (immunized), or with a placebo (non-immunized; 
Table  1). The recombinant proteins were expressed and 
purified as described in Bager et  al. [18]. Immunization 
was done using 100 µg protein in 0.5 mL of protein buffer 
and 0.5 mL Freund incomplete adjuvant (Sigma). For sol-
uble proteins (GtxA-N and FlfA), soluble protein buffer 
(50 NaP, 150 NaCl, 0.5 mM TCEP, 10% glycerol; pH 7.5) 
was used, while insoluble protein buffer (100 mM sodium 
phosphate [pH 7.4], 0.15  M NaCl, 8  M urea) was used 
for the insoluble protein GtxA-C. The non-immunized 
group received 0.5 mL soluble protein buffer and 0.5 mL 
Freund incomplete adjuvant (Sigma). Two subcutaneous 
immunizations were performed in the neck with 2 weeks 
of separation.
Challenge experiments
Three weeks after the second immunization, all groups 
were challenged with G. anatis (Table 1). All strains, kept 
at −80 °C, were incubated at 37 °C on BHI blood agar in 
a closed plastic bag. One colony of each strain was inoc-
ulated into BHI broth and incubated at 37 °C overnight. 
Table 1 Immunization and challenge
Immunization with one of three recombinant proteins was done at day 0 and 14, 
followed by challenge with a G. anatis strain at day 35.
a  A total of 25 birds showed feather pecking behavior and were removed 
from the study between day 14 and day 35, in order to prevent development 
cannibalism among the birds.
Protein Challenge strain No. of birds (day 0/35)a
GtxA-C 7990 20/19
GtxA-N 20/19
FlfA 20/17
Placebo 20/17
GtxA-C IPDH 697-78 20/20
GtxA-N 20/20
FlfA 20/20
Placebo 20/15
GtxA-C 12656-12 40/38
GtxA-N 40/39
FlfA 40/36
Placebo 40/35
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The following day, 10  mL culture was transferred to 
fresh BHI and incubated until reaching early exponential 
growth phase. Each bird received 1 mL of the inoculum 
intraperitoneally, corresponding to 108 CFU/mL.
Post mortem examination
After euthanasia at 48  h post challenge, gross lesions 
found in the peritoneum, ovary and oviduct were 
recorded and scored from 0 to 5 according to sever-
ity (Table 2). When analyzing the data, a binary division 
of the lesion scores was made according to presence or 
absence of a protective response (Table 2). Lesion scores 
0, 1 and 2 were regarded as inflammatory reaction with-
out significant infection and considered as a protective 
response against infection. Lesions scores 3, 4 and 5 were 
regarded as inflammation with infection and consid-
ered as a response with no protection, i.e., infection had 
overwhelmed the inflammatory response. Furthermore, 
swabs were sampled from the peritoneum, ovary and 
three fixed points in the oviduct; infundibulum, magnum 
and uterus. All swabs were streaked on BHI blood agar 
plates and incubated in a closed plastic bag for 18  h at 
37  °C. The growth of G. anatis was scored from 0 to 4: 
0 (no colonies), 1 (<10 colonies), 2 (10–200 colonies), 3 
(>200 colonies), and 4 (dense/florid growth/distinction of 
colonies not possible). The total bacterial load was calcu-
lated by summation of all scores giving each bird maxi-
mal total score of 20.
Collection of sera
Collection of sera for the ELISA was done before each 
immunization, before the challenge, and before euthana-
sia of birds included in the cross-protection study (exper-
iment 2). Briefly, 3 mL blood was drawn aseptically from 
the brachial vein with cannula and syringe. All blood was 
stored at 5  °C until the next day. Sera were collected by 
centrifugation (10 min, 1800 × g), and stored at −20 °C 
until further use.
ELISA
Wells in microtiter plates (Nunc-Immuno™ MicroWell™ 
96-Well Plates, Thermo Scientific) were coated over-
night at 4  °C with 0.5  µg recombinant protein (48 wells 
per protein) diluted in carbonate-bicarbonate buffer (pH 
9.6) (Sigma-Aldrich). Each well was washed three times 
using 350 µL wash buffer (PBS + 0.05% Tween 20). The 
wells were blocked 2 h at room temperature with 200 µL 
blocking solution (PBS + 0.05% Tween 20 + 2% bovine 
serum albumin (BSA)) and washed once with wash 
buffer. Serum of birds from the same group was pooled 
for each time point yielding four pools of serum; GtxA-
N, GtxA-C, FlfA, and placebo. The antibody titers from 
the vaccinated groups were obtained using serial three-
fold dilutions of chicken serum ranging from 1:300 to 1: 
656 100 while serial twofold dilutions, ranging from 1:300 
to 1:409 600 were used for the non-immunized group. In 
all plates, serum from the corresponding non-immunized 
Table 2 Scoring of lesions in birds infected with Gallibacterium anatis
48 h after challenge all birds were euthanized and scoring of lesions was done accordingly. Scores 0, 1 and 2 were regarded as inflammatory reaction without 
infection and considered as a protective response against infection. Scores 3, 4 and 5 was regarded as inflammation with infection and considered as no protection of 
the response, i.e., infection had overwhelmed the inflammatory response.
Organ Description Score Protective response
Peritoneum Normal 0 Yes
Mild cloudiness 1
Moderate cloudiness and serous exudates 2
Moderate cloudiness and serous exudates with fibrin spots 3 No
Complete cloudiness and local fibrinopurulent exudates 4
Complete cloudiness and diffuse fibrinopurulent exudate 5
Ovary Normal 0 Yes
Mild vascular congestion. No deform follicles 1
Moderate vascular congestion. Max. one deform follicle 2
Complete vascular congestion and serous exudates with fibrin spots. Deformed follicles 3 No
Complete vascular congestion and fibrinopurulent exudate 4
Complete vascular congestion, fibrinopurulent exudate and deformed follicles 5
Oviduct Normal 0 Yes
Vascular congestion 1
Vascular congestion, edema and serous exudates 2
Vascular congestion, edema and local fibrinopurulent exudates 3 No
Vascular congestion, edema and diffuse fibrinopurulent exudates 4
Vascular congestion, edema, diffuse fibrinopurulent exudates and necrosis 5
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group was included as control. All dilutions were pre-
pared in triplicates in diluting buffer (PBS  +  0.05% 
Tween 20  +  0.1% BSA), 100  µL of each dilution was 
added in triplicates and plates were incubated 1  h at 
37  °C. For each protein, secondary antibody alone was 
used as a measure of background, while diluting buffer 
alone was used as a negative control. Following incuba-
tion, the wells were washed and 100  µL polyclonal goat 
anti-chicken IgG (Fc): HRP (AbD Serotec, diluted 1:4000 
in diluting buffer) was added to each well. The plates 
were incubated 1 h at 37 °C and washed. To detect bind-
ing, 100  µL TMB substrate (Sigma) was added to each 
well. The plates were incubated 2 min, the reaction was 
stopped by adding 100 µL 1 M HCl and the absorbance 
was read at 450 nm by use of a PowerWave XS spectro-
photometry (BioTek Instruments). Linear regression was 
done on the descending, linear section of the resulting 
sigmoid plot and the average background score plotted 
horizontally. The titer for each group was then found as 
the intersection between the background average and the 
linear regression line.
Statistical analysis
All analysis of was done with SAS, version 9.3 (SAS 
Institute inc., Car, NC, USA). Lesion scores were com-
pared using Fishers exact test. Bacteriology scores were 
compared using Wilcoxon Ranked test. Mean values of 
ELISA-titers were compared with one-sided t test. P-val-
ues below 0.05 were regarded as significant.
Results
Lesions
After 48 h of challenge, lesions found in all the challenged 
groups were local to diffuse peritonitis with varying 
amounts of purulent material. The exudates varied from 
serous, fibrinous clots to confluent, purulent material. 
Vascular engorgement of the ovary, oviduct and perito-
neum was also found with purulent oophoritis and fol-
liculitis involving one or more follicles. Regression and 
deformation of the ovarian follicles were found in some 
cases. Exsudative focal or diffuse salpingitis was found in 
few birds with serous or purulent material. Overall, strain 
7990 caused the most severe lesions in the birds, which 
were mostly located in the peritoneum and the ovary. 
The birds infected with strain IPDH 697-78 did not show 
lesions in the oviduct regardless of immunization status. 
In regard of strain 12656-12, lesions were found in the 
peritoneum, ovary and oviduct. No lesions were found at 
the site of injection. The lesion scores are summarized in 
Figure 1.
The effect of immunization of the recombinant pro-
teins differed depending on the challenge strain used. 
Immunization with any of the three proteins had no 
effect on the lesions scores when challenging with strain 
7990 as compared to the non-immunized controls. In the 
groups challenged with strain IPDH 697-78, significantly 
lower lesions score in the peritoneum (P  =  0.006) and 
the ovary (P = 0.02) was found after immunization with 
Gtx-N. Also immunization with FlfA caused lower lesion 
scores in the peritoneum (P =  0.006) when challenging 
with strain IPDH 697-78. Protection from the homolo-
gous strain 12656-12 was found when immunizing with 
Gtx-N (peritoneum: P = 0.03; ovary: P < 0.0001 and ovi-
duct: P  <  0.0001), Gtx-C (peritoneum: P =  0.02; ovary: 
P  =  0.04; oviduct: P  <  0.0001) and FlfA (peritoneum: 
P = 0.03; ovary: P = 0.03; oviduct: P = 0.04).
Bacteriology
All the birds were positive for G. anatis at the initiation 
of the experiment. The isolation rates of G. anatis in pure 
culture from organs from the different groups are sum-
marized in Figure  2. In the birds challenged with strain 
7990, only immunization with FlfA resulted in lower bac-
terial isolation rates (P = 0.01). In contrast, significantly 
lower scores were found between the non-immunized 
and the immunized groups challenged with strain 12656-
12 (P-values for GtxA-C: 0.0002, Gtx-N: 0.001, FlfA: 0.01) 
and with strain IPDH 697-78 (P-values for GtxA-C: 0.04, 
Gtx-N: 0.003, FlfA: 0.027).
Antibody titers
Birds immunized with any of the three recombinant 
proteins generated a protein-specific serological IgG 
response (Figure  3) as compared to the birds receiving 
buffer and adjuvant. This IgG level remained elevated 
compared to prior immunization for the whole immu-
nization period in all the groups. However, after the 
challenge with G. anatis, all groups of birds showed a 
decrease in the protein-specific IgG level. No difference 
was observed in titer levels between groups challenged 
with the different strains of G. anatis, and no difference 
in titer levels was found between the sampling points for 
the non-immunized controls.
Discussion
The aim of this study was to evaluate whether three 
recombinant proteins, previously described as major vir-
ulence factors of G. anatis [6] and potential immunogens 
[18, 20], could induce a cross-protective response against 
three different strains of G. anatis. Both FlfA and GtxA-
N have previously been demonstrated to induce a protec-
tive immunity towards the homologous strain 12656-12 
[18, 20], however, the cross-protective potential has not 
been investigated up until now. The results presented in 
this study showed that all three antigens induced a sig-
nificant rise in protein-specific antibodies, as well as a 
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protective immune response measured by lesion scores 
and bacterial re-isolation scores, against one or more 
of the three strains included in the challenge. However, 
none of the proteins were able to elicit full protection 
against all three bacterial strains. Relying on a single pro-
tein for cross-protective immunization therefore appears 
insufficient using the current protocol, and future stud-
ies investigating combinations of immunogens and/or 
Figure 1 Lesion scores in immunized or non-immunized birds 48 h after challenge. The columns show the number of birds with a 
protective response (white bars) or a non-protective response (black bars). Groups were immunized twice with GtxA-N, GtxA-C, FlfA or buffer only 
(placebo), prior to challenge. Significant differences (P < 0.05) to the control group are marked with *.
Figure 2 Re-isolation of G. anatis in immunized or non-immunized birds 48 h after challenge. The growth of G. anatis was scored 0–5: 0 
(no colonies), 1 (<10 colonies), 2 (10–200 colonies), 3 (>200 colonies), and 4 (dense/florid growth). The total bacterial load was calculated by sum-
mation of all scores. Significant differences (P < 0.05) to the control group are marked with *.
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additions of other immune enhancing compounds are 
needed.
G. anatis is a widespread opportunistic pathogen and 
constitutes part of the normal microbiota of the lower 
reproductive tract and the upper respiratory tract of 
egg-laying hens [1]. The hens used in the present study 
were all positive for G. anatis in the clocae. To avoid 
interference of this finding naïve or SPF-hens could be 
used. However, both alternatives have downsides to the 
outcome of the study. The dispersion of G. anatis among 
egglaying hens makes it difficult to find naïve hens [1]. 
SPF-hens is declared free of a list of pathogens, however, 
G. anatis is not included and to the authors knowledge 
therefore not known to be free from G. anatis. Fur-
thermore, the intention of this vaccine is that it should 
be used in the broad population of egg-laying hens and 
therefore, a strong vaccine candidate should be able to to 
protect against infection under such circumstances.
The vast genetic diversity among G. anatis isolates 
has been described in several studies through analy-
sis of genomic data [10, 22]. Additionally, in  vivo stud-
ies have indicated that there is a difference in the lesion 
types found using different isolates of G. anatis [5]. This 
diversity in pathogenicity and virulence among different 
strains are also confirmed in this study. Challenge infec-
tions with the Mexican strain 7990 caused the highest 
Figure 3 Titer values of protein specific IgG in serum. Sera was obtained and analyzed from immunized and non-immunized birds before 
each immunization, before challenge, and 48 h after challenge. Sera from non-immunized birds did not show any significant differences at the dif-
ferent time-points and are therefore represented with one bar. Significant differences (P < 0.05) to the control group are marked with *.
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lesions scores, which is in good agreement with previous 
findings showing that this isolate has a high in vivo viru-
lence [5]. In contrast, strain IPDH 687-78 did not cause 
any lesions in the oviduct. Strain 12656-12 has previously 
been used in intraperitoneal challenge models and found 
to cause lesions in both the peritoneum, oviduct and 
ovary [8, 18, 20, 21]. These differences in the virulence 
and pathogenicity between different strains of G. anatis 
confirm the need for a broadly protective vaccine strat-
egy and strongly suggest that ability to protect against 
heterologous challenge will be a critical limitation of suc-
cessful vaccination against G. anatis.
Full in  vivo protection against the homologous chal-
lenge was confirmed for GtxA-N and FlfA [20, 21], as 
well as for GtxA-C, for which the immunogenic abilities 
has only previously been tested in  vitro [18]. A cross-
protective potential of GtxA-N, defined by lower lesion 
scores in the peritoneum and the ovary and lower re-iso-
lation rates, were observed when challenging with strain 
IPDH 697-78. As no lesions were found in the oviduct 
of the non-immunized birds challenged with this strain, 
GtxA-N can be described as giving full protection using 
this challenge model. The difference in immunogenic 
potential between the C- and N-terminal of GtxA has 
also been seen in the RTX-toxin produced by P. multo-
cida, were the C-terminal has been found to provide 
the best protection [23]. Immunization with FlfA also 
showed cross-protective potential by lowering the lesion 
scores in peritoneum and, although non-significant, in 
the ovary after challenge with strain IPDH 697-78. Addi-
tionally, re-isolation scores from birds challenged with 
strain IPDH 697-78 also showed that all three proteins 
were able to reduce these.
While the above-mentioned results are encourag-
ing, this study had limitations. Firstly, no protection was 
observed in the birds challenged with strain 7990, and 
secondly, high lesions scores were found in all groups 
challenged with strain 7990, although re-isolation of G. 
anatis was significantly lower for birds immunized with 
FlfA. As mentioned above, strain 7990 of G. anatis has 
previously been found to have a high in  vivo virulence 
potential [5] and this could influence the results. To 
improve the level of protection, several possibilities are 
available, such as immunization with combined antigens 
[24] and/or alternative delivery methods [25].
The level of specific IgG found in serum shows that 
all three recombinant proteins used for immunization 
elicited an antigen-specific immune response following 
the initial immunization, despite the different outcomes 
of the challenges. This demonstrates that a high level of 
protein-specific antibodies does not automatically lead to 
protection. Likewise, a study using a reverse vaccinology 
approach used to identify antigens for a vaccine against 
P. multocida screened 71 proteins and found them all to 
be immunogenic, but only one protein actually induced 
protection following immunization [15].
All birds had low, yet detectable levels, of protein-
specific antibodies prior to the initial immunization as 
seen in previous studies [18, 20]. This was not surprising 
as all birds cultured positive for G. anatis from the cloa-
cal swabs. However, as all three G. anatis strains caused 
infection in the non-immunized birds in the control 
groups, this background level of antibodies was not ade-
quate to protect against challenge. Thus, a mucosal pres-
ence of resident strains of G. anatis does not appear to 
induce a protective immune response.
Based on the present investigation, we conclude that 
at least two of the tested vaccine prototypes, GtxA-N 
and FlfA, elicit a promising, cross-protective immune 
response and therefore have a considerable potential 
for the development of a serotype-independent vaccine 
against G. anatis. To provide a higher degree of serotype-
independent protection, future investigations should aim 
at identifying efficient combinations of immunogens with 
immune-stimulatory additions. Furthermore, the effect 
of vaccination on production performance indicators 
including morbidity, mortality and egg-laying should be 
investigated.
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